RAMM PHARMA CORP - RAMMF STOCK NEWS

RAMM Pharma Corp. has appointed José Roldan as interim Chief Financial Officer, effective immediately, following Guillermo Delmonte's medical leave. Roldan, a public accountant with significant cannabis industry experience and a background with KPMG Uruguay, aims to enhance the company's financial oversight. RAMM Pharma, a leader in cannabinoid pharmacology, operates in Uruguay and Europe, focusing on cannabinoid pharmaceuticals and hemp-based products. The company is also developing a range of new products across various stages of approval.

RAMM Pharma Corp. has announced the acquisition of HemPoland S.p.a. Z.o.o. from The Green Organic Dutchman for C$1.2 million. This strategic move enhances RAMM's access to HemPoland's distribution network and premium hemp brands. The acquisition follows RAMM's previous purchase of Canapar Corp. in 2021, further solidifying its foothold in the European market. RAMM, recognized for its cannabinoid pharmacology, operates internationally, with pharmaceutical products approved for sale in various Latin American countries and significant operations in Europe.

RAMM Pharma Corp. announced its intention to initiate a normal course issuer bid (NCIB) to purchase up to 5% of its currently issued and outstanding common shares. The NCIB is set to commence around August 22, 2022, and will last for 12 months. Shares will be bought on the Canadian Securities Exchange (CSE) at prevailing market prices and subsequently cancelled. This move is a response to the company's assessment that its shares are undervalued. RAMM Pharma is a leader in cannabinoid pharmacology, with operations in Uruguay and Italy.

On February 22, 2022, Ramm Pharma Corp. (CSE: RAMM) announced that it would not meet the deadline of February 28, 2022, for filing its annual audited financial statements for the year ended October 31, 2021. The Ontario Securities Commission indicated that a cease trade order (CTO) will be issued due to this delay. The Company expects to file the required documents before the end of the week to revoke the CTO. Ramm Pharma specializes in cannabinoid pharmaceuticals and operates in multiple countries, including Uruguay and Italy.

RAMM Pharma Corp. (CSE: RAMM) has applied for a temporary management cease trade order (MCTO) due to delays in filing its 2022 financial statements, which include audited financials and certifications. The company is unable to meet the February 28, 2022 deadline due to complexities from an acquisition and a change of auditors. While the company remains confident in its ability to finalize the filings, it anticipates a three-week delay, expecting to complete the necessary preparations within two months. RAMM Pharma is not subject to insolvency proceedings.

RAMM Pharma Corp. (CSE: RAMM) updates on its European operations and regulatory advancements. The company, through Canapar Corp., aims to be a leader in Europe's cannabis sector with the continent's largest extraction facility, expected to achieve EU-GMP standards in 2023, producing 5,000 kg of CBD annually. Regulatory changes in Germany and France enhance RAMM’s growth potential in the $37 billion EU cannabis market by 2027. Additionally, RAMM has streamlined operations post-Canapar acquisition, reducing costs. Interim CFO Guillermo Delmonte replaces departing Guillermo Varela.

RAMM Pharma Corp. has welcomed France’s new regulatory framework that permits the use of the entire hemp plant for CBD production, setting a THC limit of 0.3%. This legislation, effective from January 1, 2022, is expected to stimulate the CBD market in Europe, potentially influencing other EU countries to follow suit. RAMM is strategically positioned through its subsidiary, Canapar Corp., which operates the largest extraction facility in Europe. The EU CBD market was valued at €1.6 billion in 2020 and is projected to reach €8.7 billion by 2030.

RAMM Pharma Corp. (CSE: RAMM) has welcomed Germany's coalition government's agreement to legalize recreational cannabis, marking a pivotal moment for the European cannabis market. Already the largest medical cannabis market in Europe, Germany's market is projected to grow to €3.2 billion by 2025 from €403 million in 2021. RAMM's vertically integrated operations, particularly through its subsidiary Canapar Corp., position the company to capitalize on this growth with its advanced extraction facility and extensive product portfolio aimed at various market segments.

On September 15, 2021, RAMM Pharma Corp. (CSE: RAMM) announced the resignation of Mr. Sergio Martines from its board of directors. The company expressed best wishes for his future endeavors. RAMM Pharma is recognized for its work in plant-derived cannabinoid pharmaceuticals and operates a pharmaceutical business in Uruguay, with products approved for sale in several Latin American markets. The company also has a presence in Europe, focusing on CBD formulations and wellness products.